BioSpace News Archive

Rakuten Medical, Inc. (Rakuten Medical) today announced the acquisition of phthalocyanine dyes, including IRDye® 700DX, from LI-COR Biosciences

Avectas, a cell engineering company that has pioneered SOLUPORE®, a transformative non-viral cell engineering technology, to enable efficient and safe genetic modification of the next generation of cell therapies, announced today that Daniel Castro has been appointed as Chief Business Officer.

Engage, a premier MEDITECH solutions provider for hospitals, announces plans to offer the MEDITECH market access to KLAS Arch Collaborative and their innovative Electronic Health Record services to better measure EHR implementation success.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET.

Strong pipeline progress in 2020 positions company well for 2021 Established proof of concept in SCD for FT-4202 Potential transformative treatment profile for IDH1 inhibitor olutasidenib in R/R/ AML Enrolling Phase 1 FT-7051 trial for prostate cancer - including patient with AR-v7 splice variants Completed successful IPO and follow-on equity offering

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20 a.m. JT on Tuesday, January 12, 2021

Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer and other diseases, and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that they have entered into an option and license agreement aimed at developing and commercializing Strand’s innovative, multi-functional mRNA treatments for solid tumors

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the Company’s plans for the buildout of its new Research and Development (R&D) and Chemistry, Manufacturing and Controls (CMC) operation which will also serve as the Company’s new headquarters in Cranbury, New Jersey

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 1,810,000 shares of common stock at a price of $8.30 per share, priced at-the-market under Nasdaq rules,

Innocoll Holdings Limited, a specialty pharmaceutical company wholly owned by Gurnet Point Capital, a private investment firm focused on health care, announced that Louis Pascarella has been named the company’s Chief Executive Officer and a member of Innocoll’s Board of Directors.